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Abstract Background: Almitrine bismesylate (AB) is a peripheral chemoreceptor agonistwhichisbelieved to improve
oxygenation of COPD patientswith chronic hypoxaemia, probably by improving the ventilationperfusionmismatch.We
studied the long-term effects of AB in COPD patients with chronic hypoxaemia.Methods: Design Prospective, rando-
mised, double-blind, placebo-controlledtrial. Setting:Eighthundredbedteachinghospitalwith a catchmentpopulationof
350 000 inhabitants.Patient recruitment:COPDoutpatients consultingbetween September 95 and September 99. Inclu-
sion criteria: (1)- COPD ( FEV1o50%). (2) PaO265mmHg. (3) Stable arterial blood gases (ABG), spirometry (S) and
clinical state. Exclusion criteria: Asthma, restrictive disease, sleep apnoea syndrome, advanced renal or hepatic disease,
peripheralneuropathy, use of respiratory stimulants or psychotrophicdrugs.Treatment:AB1mg/kg/day (weighto75 kg
= 50mg/day;weight75 kg= 100mg/day) in anintermittent schedulewithrestingperiodsof1monthafter thethird,6th
and 9th months during 1 year. Instrumentation: Stabilisation period: S, ABG.Run-in period: S, ABG, 6-min walking test
(WT), nocturnalpulse oximetry (NP) and qualityof life evaluation (CRQ).Third,6th and 9thmonths: S,ABG.End of the
study: S, ABG,WT,NP,CRQ. Statistics: ANOVA for repeated measurements. Results:Two hundred and eighty-nine pa-
tientswereevaluatedand 81wereincludedinthe study.Sixty-sixwere followed for 6months,53 for 9months and 42 for1
year. Almitrine and placebo groups did not present significantdifferences in ABG and S in the 6th,9th and12thmonths.
EvolutioninWT,NPand CRQwere similar inthe two groups.Norelevant side-effectswere detected: only twopatients
stopped treatment (one placebo and one AB).Conclusion: In anintermittent schedule, althoughwell tolerated, atdoses of
1mg/kg/day,ABwasnoteffectiveinlong-termtreatmentofchronichypoxemia in COPDpatients.r2003 Elsevier Science Ltd.
Allrights reserved.
doi:10.1053/rmed.2003.1486, available online at http://www.sciencedirect.com
Keywords almitrine bismesylate; COPD; chronic hypoxaemia.INTRODUCTION
Chronic respiratory failure is the end stage of COPD.
Home oxygen therapy is the only treatment which has
been demonstrated to improve survival of COPD pa-
tients with chronic respiratory failure (1,2). Despite this
improvement in survival, the mortality of patients re-
ceiving long-term oxygen therapy (LTOT) is around 50%
at 3 years (3,4) andnobodyhasbeen able to demonstrate
whether or not LTOT improves the quality of life of
COPD patients.The issue is particularly important since
it has been demonstrated that the quality of life of these
patients is extremelypoor (5,6) andmany aspects ofoxy-
gen therapy are potentially troublesome.
The poor results of LTOT have spurred the search for
coadjuvant or alternative pharmacological treatments.Received 28 May 2002, accepted in revised form 28November 2002
Correspondence should be addressed to Dr.C.Domingo,Corporacio¤
ParcTaul|¤ , ParcTaul|¤ s/n 08 208 Sabadell, Barcelona, Spain.Fax 34 93 716
0646 E-mail address: cdomingo@cspt.esAlmitrine bismesylate (AB) is a peripheral chemorecep-
tor agonist which is believed to improve oxygenation,
probably by improving the ventilation perfusion mis-
match. According to prescription guidelines, oral admin-
istration of this treatmentmaymean that, in borderline
cases, long-term oxygen therapy can be discontinued,
delayed or even avoided. AB treatment could also im-
prove oxygenation in patients on LTOT during the hours
that they are not receiving supplementary oxygen. The
drug was commercialised in Europe in the 80s, but its
use in clinical practice has been limitedby its side-e¡ects
(peripheral neuropathy and dyspnea) (7^12). These side-
e¡ects are dose dependent and several studies seem to
demonstrate that the treatmentmay retain its ability to
improve oxygenation even at lower dosages which de-
crease the incidence of side-e¡ects (13^15). Although
COPD is a disease with few e¡ective therapeutic re-
sources, and despite the bene¢cial results published in
the literature with lower doses of this drug, the fact is
that AB is little used in clinical practice. Nonetheless
TABLE 1. Instrumentation.
T2 T1 T0 T3 T6 T9 T12*
Spirometry X X X X X X X
ABG X X X X X X X
Walking test X X
Nocturnalpulseoximetry X X
C.R.Q. X X
Chest-X-ray X
E.C.G. X
T=time in months. ABG=arterial blood gases.
CRQ=Chronic Respiratory Disease Questionnaire.
ECG=electrocardiogram.
*Patients who were dropped out for external reasons
were evaluated withWT,NP and CRQ at the time they
were dropped out.
600 RESPIRATORYMEDICINEinterest in the e¡ects of this drug combined with nitric
oxide in acute respiratory distress syndrome appears to
be growing (16).
We studied the long-term e¡ects of AB in hypoxaemic
COPDpatients, using lowdoses (1mg/kg/day) in an inter-
mittent schedule which included resting periods of 1
month after the 3rd, 6th and 9thmonths.
METHODS
This prospective, randomised, double-blind, placebo-
controlled study was conducted in the Corporacio¤ Parc
Taul|¤ in Sabadell (Barcelona, Spain), 800-bed teaching
hospital with a catchment population of 350 000 inhabi-
tants.The study was approved by the ethical committee
of the hospital and by the Direccio¤ n General de Farma-
cia, a body a⁄liated to the Spanish Ministry of Health,
equivalent to the Food and Drug Administration in the
USA. The study was conducted independently of phar-
maceutical ¢rms. It was funded by a grant of the Funda-
cio¤ ParcTaul|¤ (FPT).The study lasted 4 years, andpatients
wererecruited from an outpatientCOPD clinic between
September1995 and September1999. Each patient in the
COPD clinic wasmonitored and e¡ortsmade to stabilise
their condition.Wehave analyseddata collectedover a15
month follow-up period from the time the patient was
clinically stable. The stabilisation period lasted the ¢rst
2 months; the 3rd month was a run-in period, and the
treatment period covered the remaining12 months.The
AB dosage was around 1mg/kg/day (weighto75kg =
50mg/day; weight 75kg = 100mg/day). It was given in
an intermittent schedulewith resting periods of1month
after the 3rd, 6th and 9th months during1year. Patients
were randomised to receive either almitrine or placebo
with the aid of a computer programme.Medication was
dispensed by the Pharmacy. Tablet presentation was
identical for AB and placebo.
All patients gave written informed consent, in accor-
dancewith the instructions of the Helsinki convention.
The inclusion criteria were: (1) Patients with COPD
(FEV150% predicted); (2) PaO2 lower than 65mmHg
during the stabilisation period, (3) stable arterial blood
gases (ABG), spirometry (S) and clinical state.The exclu-
sion criteria were: asthma, restrictive disease, sleep ap-
noea syndrome, advanced renal or hepatic disease,
peripheral neuropathy, use of respiratory stimulants or
psychotropic drugs.
Patients were recruited in an outpatient COPD clinic
and they were stabilised clinically, spirometrically and in
their ABG. The stabilisation period lasted more than 2
months.During the stabilisation period, ABG and spiro-
metry weremeasured in each visit.Our statistical analy-
sis only documented the last 2 months of the
stabilisation period. During the run-in period we mea-
suredABG, S, 6-minwalking test (WT), nocturnal pulseoximetry (NP) and quality of life using the Chronic Re-
spiratory Disease Questionnaire (CRQ). During the
3rd, 6th and 9thmonthswemeasuredABGand spirome-
try. At the end of the study we repeated the measure-
ments of the run-in period (ABG, S, WT, NP, CRQ)
(Table1).
Description ofmeasurements
Spirometry was done in aMedGraphics system1070 Ser-
ies 2E/1085. Mediterranean population reference values
were used in spirometry (17).
Arterial blood gases were measured with a radial
puncture using local anaesthesia while the patient was
breathing room air. In patients receiving LTOT, oxygen
therapy was stopped half an hour before ABG determi-
nation. ABGwasmeasuredwith a Radiometer ABL 500.
TheWTwas performed in a corridor inside the hospi-
tal.The patient was asked to walk as far as he could for
6min. The patient did not receive any encouragement
and could stop when he wished.Oxygen saturation was
measuredwith an Ohmeda Biox 3700e pulse-oximeter.
Dyspnoeawasmeasuredwith a visual analogic scale at
the beginning and end of theWT.
NPwasmeasuredbreathing room air using anOhme-
da Biox 3700e pulse oximeter. A computer programme
measured thepercentage of time thepatient’s oxygen sa-
turationwas below 90%, 85% and 80% (CT90,CT85 and
CT80), respectively, as well as the number of oxygen de-
saturations above 4%.We studied themorphologyof the
NP to exclude patients with sleep apnoea syndrome
(SAS). Patients with suspected SAS in the NP were stu-
died with a respiratory polysomnography (Sibel Home
300, Sibel S.A., Barcelona, Spain) to completely rule out
this diagnosis.
LONG-TERMEFFECTSOFALMITRINE 601Quality of life was measured with the Chronic Re-
spiratory Disease Questionnaire described by Guyatt et
al. (18,19), which consists of 20 items classi¢ed in four do-
mains: dyspnoea, fatigue, emotional function and mas-
tery. Each item has seven answers. The dyspnoea
domain is individualised for each patient. The score in
each dimension is calculated by dividing the addition of
each answer by the number of items in each dimension.
The total score is between1and 7.The higher the score,
the better quality of life. This questionnaire has been
translated into Spanish and validated (20).
Evaluation of side-e¡ects: Side-e¡ects were evaluated
clinically. Peripheral neuropathy was also evaluated clini-
cally in patients who complained of paresthesia or other
symptoms suggesting peripheral neuropathy.
Assuming a correlation of 0.75 between the ¢rst and
the lastmeasurement and a common standard deviation
of 7, a sample of 23 patients per arm would provide at
least 90% power to detect a di¡erence of 5mmHg in
PaO2 in themeanchanges frombaseline to12monthsbe-
tween the two arms, using a two-sided t-test with a 0.05
type I error.
Statistical analysiswas doneusing theANOVAtest for
repeated measurements using the computer program
Spss 8.0. Data analysis was done separately at the 6th,
9th and12thmonth follow-up.
RESULTS
We evaluated 289 patients, of whom 81were included in
the study. Sixty-six patients were followed up for 6
months, 53 for 9 months and 42 for 12 months. The pa-
tients were recruited from a monographic outpatient
clinic dedicated to patients with chronic respiratory dis-
ease. In order to get an homogeneous group of patients
with COPD, we were very careful in patient selection.
Two hundred and eight patients could not enter the
study. The reasons why these patients could not enter
the study are as follows: COPD diagnosis incorrect
(29%), patients lost to follow-up (22%), patients not ad-
justing to ABG criteria (22%), patients impossible to sta-
bilise (11%), patients died during the stabilisation period
(7%), exclusion criteria ( 3%), patients included in other
studies (3%), patients not giving informed consent ( 2%)
and other reasons (1%). Diagnosis of patients excluded
from the study in whom the diagnosis of COPD was in-
correct were: SAS (30%), restrictive disease (27%),
bronchiectasis (16%), obesity and hypoventilation (10%),
cardiac disease (6%) and other diseases (11%). Of the 81
patients who started the study, 39 could not complete
the 12 month follow up for the following reasons: nine
patients died, eight had a bad treatment compliance,
one had possible side-e¡ects, three had interference
with other disease, four hadmissing data and14 because
the study was stopped for external reasons against thepatients and investigatorswilling, motivatedby a reorga-
nisation ofmedical assistance in the hospital. All patients
of this last group completed a period of 6 month follow-
up. Six had to stopbefore the 9thmonth andeightbefore
the 12th month. Although the study was designed to
evaluate WT, NP and CRQ at the end of the 12 month
follow-up, these variables were analysed in the 6th and
9 month in some of the14 patients who had to drop out
for externalreasons.Ninepatients diedduring the follow
up. In seven patients, death was related to COPD, one
patient was diagnosed of an oesophageal cancer and the
other one died following a suicide attempt.This last pa-
tient had a very impaired quality of life before being in-
cluded in the study. Five patients were receiving
almitrine and four were receiving placebo.
Mean age of the patients was 7073 years.Their mean
height was 16076 cm and their mean weight was
69713kg. In total, 97.5% had been heavy smokers, 56%
were receiving LTOT. S (mean7SD) showed: FVC
25577550ml (71715%); FEV1 8777294ml (35711%);
FEV1/FVC 34%79%. ABG (mean7SD) showed: PaO2
5677mmHg; PaCO2 5076mmHg. Forty-one patients
were assigned to almitrine group and 40 patients were
assigned to placebo group. Fifty-seven patients received
daily a tablet of 50mg and 24 patients received daily two
tablets (100mg) of almitrine or placebo in a randomised
way.There were no statiscally signi¢cant di¡erences be-
tween the AB and the placebo group in terms of age, use
of LTOT, spirometry, ABG, walking test and CRQ. The
AB group presented a lower weight than the placebo
group (P=0.01), that was due to an outlayer in the latest
group. Nocturnal pulseoximetry variables (mean SaO2;
CT90; CT85; CT80) were signi¢cantly di¡erent in both
groups (Table 2).
Evolution of ABG:PaO2: ANOVA for repeatedmeasure-
ments showedno di¡erencesbetween the AB and place-
bo groups in terms of the evolution of the PaO2 after 6,9
and12 months of follow up (Table 3).There was a statis-
tically signi¢cant improvement in the evolution of PaO2
of the whole sample, after 6, 9 and12 months of the fol-
low-upperiod.Patientswere divided in subgroups on the
basis of oxygen therapy and hypercapnia. No signi¢cant
di¡erence couldbe demonstratedbetween almitrine and
placebo treatment.We also investigated whether there
was a subgroup of responders to AB, as some authors
have reported in literature (15), but the rate of response
was similar in AB and placebo groups.
PaCO2: ANOVA for repeated measurements did not
demonstrate di¡erences in the evolution of the PaCO2
after 6, 9 and 12 months of follow-up between the AB
and the placebo group. PaCO2 remained stable during
the12 months of the follow up period.
Evolution of spirometry: We found a signi¢cant decline in
FEV1inbothgroups of patients.This declinewas quanti¢ed
at around 70ml. No signi¢cant di¡erence was observed
between the groups in either FVC, FEV1or FEV1/FVC.
TABLE 2. Patients characteristics at baseline.
T2 T1 T0 P-value
Age(Years) Almitrine 70.876 0.471*
Placebo 69.678
Weight (kg) Almitrine 65.8714 0.01*
Placebo 73712
PaO2(mmHg) Almitrine 56.276 56.276 5677 0.1
w
Placebo 5576 57.376 56.577
PaCO2(mmHg) Almitrine 50.875 52.176 51.976 0.537
w
Placebo 49.476 48.976 49.776
FEV1(ml) Almitrine 8327248 8167299 8327292 0.387w
Placebo 9067333 8887302 9357297
WT (mean SaO2%) Almitrine 84.177 0.243*
Placebo 85.874
WT (meters) Almitrine 322773 0.37*
Placebo 336766
NP (mean SaO2%) Almitrine 87.574 0.05*
Placebo 89.573
CRQ Almitrine 4.671 0.169*
Placebo 4.271
*Student;sT-test.
wANOVAfor repeatedmeasurements.
WT: walking test;NP: nocturnalpulseoximetry;CRQ:Chronic Respiratory Disease Questionnaire.
TABLE 3. Evolution of PaO2 at 6,9 and12 months.
T0 T3 T6 T9 T12 P-value*
12 months (N=42) AB (n=18) 57.278 60.579 59.479 61.4710 61.1711 0.853
P (n=24) 57.376 58.478 59.579 59.178 60.778
Global (n=42) 57.277 59.378 59.579 60.179 60.979 0.01
9 months (N=53) AB (n=27) 56.277 58.879 58.678 59.679 0.5
P (n=26) 57.376 58.778 59.479 5978
Global(n=53) 56.877 58.878 5979 59.379 0.01
6 months (N=66) AB(n=36) 55.677 59.179 5878 0.99
P(n=30) 56.776 58.478 59.179
Global(n=66) 56.177 58.878 58.579 0.02
T = time inmonths.N= number.AB= almitrine.P=placebo.PaO2 is expressed inmmHg.Mean7Standard deviation.
*ANOVAfor repeatedmeasurements
602 RESPIRATORYMEDICINEEvolution of 6minute walking test: Evolution of mean
oxygen saturation during the walking test did not show
di¡erences between the AB and the placebo group. Evo-
lution of the distance walked by the patients was similar
in the two groups.
Evolution of nocturnal pulse oximetry: The evolution of
mean oxygen saturation, CT90, CT85 and CT80 during
nocturnal pulse oximetry did not di¡er between AB
and the placebo groups.
Evolution of quality of life: No changes were found in
quality of life as measured with the chronic respiratorydisease questionnaire. Evolution of quality of life was si-
milar in the two groups.
Side e¡ects: Only one patient was excluded for
possible side-e¡ects. This patient complained of
weakness in lower extremities. Neurologic examination
was normal and he refused electromyographic
studies.
Evolution of body weight was monitored. AB and
placebo groups lost 2.6 and 2.9kg, respectively.
There were no signi¢cant di¡erences between both
groups.
LONG-TERMEFFECTSOFALMITRINE 603DISCUSSION
The ¢rst results of studieswith AB raisedgreat expecta-
tions and seemed to suggest an alternative or coadjuvant
therapy to LTOT for the treatment of respiratory failure
in COPD. The optimism was tempered by the descrip-
tion of peripheral neuropathy as a major side-e¡ect (7).
The ¢rst long term, double-blind, placebo-controlled
studies in COPD patients using doses of100^200mg/day
showed an improvement in PaO2 greater than 5mmHg,
but tolerance was poor, and the number of side-e¡ects
such as dyspnoea and peripheral neuropahty was unac-
ceptable (12,21). These improvement in PaO2, together
with the longhalf-life ofABmade itnecessary to conduct
new studies using lower doses and incorporating an ac-
tive search for side-e¡ects.The use of the drug in clinical
practice decreased.
Dyspnoea, one of the side-e¡ects described, was at-
tributed to an increase in pulmonary artery pressure
that had been observed after acute administration of
AB (10). Several studies were conducted to determine
the long-term e¡ects of AB on pulmonary artery pres-
sure and dyspnoea. PreŁ faut (21) using high doses of AB
(1.5mg/kg/day), B˛hning and Winkelman (22,23) in ob-
servational studies with 75mg/day andWeitzenblum (13)
in a double-blind, placebo-controlled study using100mg/
day in an intermittent schedule found no increase in pul-
monary arterypressure or dyspnoea after long-term ad-
ministration of AB. In our study, we did not observe any
increase of dyspnoea attributed to AB, as a side-e¡ect.
Incidence of peripheral neuropathy in the literature is
high in COPD patients before treatment with AB, but it
does not clearly worsen with lower doses of AB. In an
open study using 75mg/day with a low number of pa-
tients Winkelmann (23) found electrophysiological
changes that were not clinically relevant. In a double-
blind, placebo controlled study using100mg/day in an in-
termittent schedule, Weitzenblum (14) did not ¢nd sta-
tistically signi¢cant electrophysiological or clinical
changes between AB and placebo groups. Bakran (24),
using 50mg/day, did not report peripheral neuropathy;
nordidGonzalez Ruiz (25) using 50^100mg/day, ormore
recently Nowak (26) who compared 75mg/day with
100mg/day in an intermittent schedule. Using 1mg/kg/
day in an intermittent schedule, Bardsley (15) found that
the electrophysiological test was normal in only 38% of
the patients before the study, but none of the patients
developedperipheral neuropathy, andparesthesiawas si-
milar in the placebo and AB group.
So low doses of AB seem to be safe.Dyspnoea and in-
crease in pulmonary artery pressure only seem to occur
after acute administration of AB, and peripheral neuro-
pathy is dose dependent andnot clinically relevant at low
doses of AB.
Open studies such as those of Winkelman (23) or
B˛hning (22) or short-term studies such as that of Bak-ran (24) found an improvement in PaO2 greater than
5mmHg. Double-blind placebo-controlled long-term
studies with a high number of patients such as those of
Weitzenblum (13,14) and Bardsley (15) using low doses in
an intermittent schedule also found an increase in PaO2
greater than 5mmHg. In their studies, Bardsley (15) and
Gonzalez Ruiz (25) divided the patients in responders
and non-responders to therapy; a patient was consid-
ered a responder if PaO2 was increased by 5mmHg or
more after AB treatment. Sixty-four per centof the sub-
jects in Bardsley’s study (15)wereresponders, and 58% in
the study by Gonzalez Ruiz (25).Only Nowak et al. (26)
found no improvement with AB.
Although AB seems to be safe with lower doses and
intermittent schedules, the results concerning its e⁄-
cacy are somewhat contradictory. Most of the studies
show an improvement in ABG, but two of them (15,25)
found a high percentage of patients (435%) that did not
respond to medication. Moreover, this medication has
not found its way into routine clinical practice despite
the limited therapeutic options in patients of this type.
All this points to the need for a new study to clarify
whether or not AB is clinically e¡ective in COPD pa-
tients.
We studied long-term e¡ects of AB at doses of 1mg/
kg/day using an intermittent schedule in a randomised
double-blind placebo-controlled study.Our study di¡ers
fromprevious studies in that it was conducted at a single
centre, thus obviating the methodological problems
caused by multicentre studies; the criteria were applied
by the same investigator to the whole population of pa-
tients.Moreover, we were very strict in the selection of
the cohortof ¢nallyrandomisedpatients, as is clear from
thevery large number of patients attended and the num-
ber of patients randomised. Sincewewanted to test the
clinical usefulness of the drug, we tested its e⁄cacy in
arterial blood gases at rest, lung function (spirometry),
oxygenation in exertion (walking test) andwhile sleeping
(nocturnal pulse oximetry). Aside from this extensive
evaluation, our study is the ¢rst to evaluate the e¡ects
of AB on patients’ quality of life. This extensive clinical
and biological evaluation was carried out over one of
the longest follow-up periods reported to date, and so
we believe that the methodological design of the study
must re£ect the clinical usefulness of AB.
We found that AB administered at 1mg/kg/day in an
intermittent schedule is a safe medication.We found no
relevant side-e¡ects, but none of the parameters stu-
died was modi¢ed. AB did not improve ABG in the 12-
month follow-up, nor in any of the measurements per-
formed after 3, 6, or 9 months.We also failed to ¢nd a
subgroup of patients with improved PaO2. Neither oxy-
gen therapy nor the degree of hypercapnia at the begin-
ningof the studymodi¢ed the evolution of PaO2.We also
tried to identify a group of responders to AB (patients
whose PaO2 improved by more than 5mmHg) as some
604 RESPIRATORYMEDICINEauthors have done (15,25), but we found a similar re-
sponse rate in the AB and placebo groups. Analysis of
other parameters such as spirometry, nocturnal pulse
oximetry, walking test and quality of life producedno re-
levant ¢ndings except for a slight non-statistically signi¢-
cant decrease in the FEV1values.
Some authors have observed an increase in nocturnal
oxygenation of this patients while receiving AB (27, 28)
or in the mean oxygen saturation during exercise test
after acute (29,30) and long-term administration (24).
We did not observe any improvement in nocturnal oxy-
genation ormean oxygen saturation of patients receiving
AB. Finally, as we said above, our study is the only study
of AB which has measured quality of life. We used the
CRQ questionnaire, which has been validated for the
Spanish population (20); the total CRQ score and its four
domains remainedunchanged after the follow-up period
and there were no di¡erences between AB and placebo
group.This illustrates that the drug was very well toler-
ated, but therewere no demonstrable clinical bene¢ts.
Our results concerning oxygenation are in agreement
with those of Nowak (26), who compared continuous
75mg/day with 100mg/day in an intermittent schedule,
¢nding a lack of improvement with 75mg/daily and only
a slight improvement in some of themeasurements with
the100mg/day intermittent schedule.Other studies (15,
25), using low doses have demonstrated that the im-
provement in PaO2 is not universal, and only 60% of the
patients may bene¢t from AB.Only the studies of Weit-
zenblum (13,14) using 100mg/day in intermittent sche-
dule, and studies with a high dosage of AB have
demonstrated a clear improvement in ABG. High doses
of AB are contraindicated by the side-e¡ects. Our do-
sagewas only slightly lower than that of100mg/day in in-
termittent schedule, and failed to show an improvement
in ABGor other parameters such as nocturnal pulseoxi-
metry, walking test and quality of life. So, if AB is e¡ec-
tive in improving oxygenation, its therapeutic range is
narrow, and it also remains to be shownwhether or not
this improvement correlates with survival as is the case
of oxygen therapy, or with other parameters such as ex-
ercise capacity or quality of life.
Our disappointing ¢ndings, the poor results with low
doses of AB found in other studies and the low prescrip-
tion of this drug in daily clinical practice by pulmonolo-
gists treating patients with chronic respiratory failure
suggest that although ABmay be e⁄cacious in some cir-
cumstances, it does not seem to be an e¡ective drug for
long-term treatment of hypoxaemia related to COPD.
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